Scancell Holdings Plc Eurogentec manufacturing agreement (7970E)

TIDMSCLP

RNS Number : 7970E

Scancell Holdings Plc

21 July 2016

21 July 2016

Scancell Holdings Plc

("Scancell" or the "Company")

Leading DNA plasmid manufacturer Eurogentec appointed to manufacture new SCIB1 material

Scancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, today announces an agreement with Eurogentec S.A, an FDA inspected CMO specialised in the GMP production of plasmid DNA and recombinant proteins, for the manufacture of new supplies of Scancell's SCIB1 ImmunoBody(R) vaccine for use in the US clinical study of SCIB1 in combination with a checkpoint inhibitor, expected to commence in 2017. Upon completion and once fully evaluated, which is expected to take approximately 9-12 months, this clinical trial material will also be available to recommence dosing of patients in the Company's long-term extension of the Phase 1/2 SCIB1 clinical study in malignant melanoma (subject to regulatory approval).

Eurogentec's biologics division produces clinical trial and commercial biopharmaceutical material compliant with current Good Manufacturing Practice (cGMP) for all major markets according to US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) requirements. The company is FDA inspected (2011, 2013, 2014) and currently manufactures a biopharmaceutical marketed in the US. In the field of plasmid DNA, Eurogentec is a recognised leading CMO having recently manufactured 150g of plasmid DNA material for a major pharmaceutical company with plans to scale the process to commercial requirements.

Dr Richard Goodfellow, CEO of Scancell, said:

"We are delighted to be working with Eurogentec, a world class manufacturer, to provide the new batch of SCIB1 material. As can be seen from the latest data from our Phase 1/2 clinical trial, SCIB1 continues to deliver compelling survival data in patients with resected stage III/IV melanoma. This new supply will not only be used in our upcoming US checkpoint inhibitor combination trial, but also enable us to recommence treating patients in the long-term extension of the Phase 1/2 study.

"Access to Eurogentec's expertise and proprietary manufacturing processes has the potential to substantially increase the yields of SCIB1 and fast-track the scale-up that will be required for future Phase III and commercial supply."

For Further Information:

Scancell Holdings Plc

 
 Dr John Chiplin, Executive 
  Chairman                                          [phone] 
  Dr Richard Goodfellow,       Scancell Holdings     [phone] 
  CEO                           Plc                  1000 
 
 Freddy Crossley (Corporate                         [phone] 
  Finance)                                           2500 
  Tom Salvesen (Corporate      Panmure Gordon        [phone] 
  Broking)                      & Co                 2500 
 
                                                    [phone] 
 Mo Noonan/Simon Conway        FTI Consulting        1000 
 

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody(R) and Moditope(R) technology platforms.

Scancell's first ImmunoBody(R), SCIB1 is being developed for the treatment of melanoma. Data from thePhase 1/2 clinical trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects. In patients with resected disease there is increasing evidence to suggest that SCIB1 may delay or prevent disease recurrence.

Scancell's ImmunoBody(R) vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system where inflammation is stimulated at the tumour site and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Pre-clinical data on a combination of SCIB1 or SCIB2 and checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune checkpoint pathways) have shown enhanced tumour destruction and significantly longer survival times than when either treatment was used alone.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that destroy tumours without toxicity. The Directors believe that the Moditope(R) platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

About Eurogentec

Eurogentec S.A., part of Kaneka Corporation, is a leading global supplier of innovative reagents, kits, specialty products and custom services. Through its three inter-related business units, the company provides high quality products to scientists involved in the life science, biotechnology, diagnostic and pharmaceutical markets. Eurogentec is fully ISO 9001, ISO 13485 certified, cGMP accredited by the Belgian Ministry of Health and approved by the US FDA for the commercial manufacturing of a biologic marketed in the US. www.eurogentec.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCKMGZNVGLGVZM

(END) Dow Jones Newswires

July 21, 2016 02:00 ET (06:00 GMT)